Clinical Trials Directory

Trials / Terminated

TerminatedNCT00407147

Procalcitonin Level to Discontinue Antibiotics on ICU Patients With no Obvious Site of Infection

ProBac - Use of Procalcitonin Level as Part of a Decision Tree to Discontinue Antibiotics When Started Empirically in the ICU in Hemodynamically Stable Patients With no Site of Infection Identified

Status
Terminated
Phase
Phase 4
Study type
Interventional
Enrollment
11 (actual)
Sponsor
Brahms AG · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to test whether a U.S. Food and Drug Administration (FDA) approved laboratory test (PCT Kryptor) can help doctors make better decisions on the need for antibiotic therapy in ICU patients with suspected infections.

Detailed description

The study is undertaken as prospective, randomized, controlled, multicenter trial. The study population, ICU patients with empiric antibiotic treatment due to suspected but unproven infection, is randomly assigned to either a Standard Care Group or a Procalcitonin (PCT) Guided Group. In the standard care group, antibiotic treatment would be based totally on clinical decision making with "traditional thought processes" (i.e., cultures, response to antibiotics, risk of untreated infection, other laboratory findings, etc.). The PCT guided group will use the same "traditional thought processes" and in addition the physician will be given access to a PCT value for Day 1 and Day 4 along with the recommended thresholds for likelihood of infection. In conjunction with other laboratory findings and clinical assessments the threshold of PCT is used to continue or discontinue empiric antibiotic treatment.

Conditions

Interventions

TypeNameDescription
DEVICEProcalcitonin assay - B.R.A.H.M.S PCT sensitive Kryptorantibiotic treatment based on clinical decision making with "traditional thought processes" used in both groups. In addition the physician will be given access to Procalcitonin values with recommended thresholds for likelihood of infection.

Timeline

Start date
2008-07-01
Primary completion
2009-06-01
Completion
2009-06-01
First posted
2006-12-04
Last updated
2012-01-18

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00407147. Inclusion in this directory is not an endorsement.